ClinicalTrials.gg
RecruitingNCT06588101SWATUpdated Jun 4, 2025

Clinical Trial Recruitment and Retention Strategies for Family Members in the ICU

An interventional study of Written informed consent with infographic and Compensation in Family Members, Recruitment and Clinical Study, sponsored by Lady Davis Institute. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Lady Davis Institute · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

There is a need to identify strategies that improve the conduct of clinical trials involving family members of intensive care unit (ICU) patients. The purpose of the present study is to evaluate recruitment and retention strategies for clinical trials involving family members of ICU patients. 4 strategies (2 recruitment and 2 retention) will be tested. Investigators will integrate the strategies into three existing studies that involve family members of ICU patients. Participants will be randomized using a 2x2 factorial design. The co-primary outcomes are recruitment percentage (participants enrolled/participants approached) and retention percentage (participants completing follow-up/participants enrolled).

Read the detailed description

Family engagement in the ICU is recommended by critical care professional societies, but insufficient evidence of its benefits for patients and family members has hindered clinical uptake. Thus, high-quality evidence is needed to promote and support family engagement practices. A specific unmet need is to identify strategies to improve the recruitment and retention of families in clinical trials in the ICU setting. The objective of this study is to evaluate recruitment and retention strategies for clinical trials involving family members in the ICU setting.

Methodological Approach: Investigators will use a Study Within a Trial (SWAT) design to embed a factorial randomized trial of 160 participants enrolled across investigator group's three ongoing studies involving family members of ICU patients: FAME, VR-Family, and NGAGE. Investigators expect 160 participants to be enrolled over a 6-month period. Participants will be randomized by 2x2 factorial design to selected recruitment and/or retention strategies. The co-primary outcomes will be (1) recruitment rate and (2) retention rate.

02

Conditions studied

  • Family Members
  • Recruitment
  • Clinical Study
  • Retention
  • Recruitment of Participants
  • Study Enrollment
  • Retention of Participants
  • Compensation Incentives
03

In context

Lead sponsor

Lady Davis Institute is the lead sponsor of 46 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has family member admitted to an intensive care unit.
  • Expected hospital stay > 48 hours
  • Able to participate in English or French

Exclusion criteria

Exclusion Criteria:

  • Has another family member participating in the trial
  • Repeat admissions within the study period
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Both recruitment strategies

    Consent form with Infographic + Large compensation

    Other: Written informed consent with infographic · Other: Compensation

  • No intervention
    Neither recruitment strategy

    Consent form + No compensation

  • Experimental
    One recruitment strategy - Infographic

    Consent form with Infographic + No compensation

    Other: Written informed consent with infographic

  • Experimental
    One recruitment strategy - Compensation

    Consent form + Large compensation

    Other: Compensation

Interventions

  • OtherWritten informed consent with infographic

    Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.

  • OtherCompensation

    Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.

06

What researchers measure

Primary outcomes

  1. Recruitment percentage

    Family member participants enrolled/ family member participants approached

    Time frame: At enrolment

  2. Retention percentage

    Family member participant completing follow-up/family member participants enrolled

    Time frame: From enrolment until 6 month follow-up completion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588101
Lead sponsor
Lady Davis Institute
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Michael Goldfarb (Attending Staff, Division of Cardiology, Lady Davis Institute) — Principal investigator
First posted
Sep 19, 2024
Start date
May 1, 2024
Primary completion
Apr 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 4, 2025

Study contacts

Jillian Kifell, MSc
Contact
jillian.kifell.ccomtl@ssss.gouv.qc.ca
5143408222 ext. 25806
Michael J Goldfarb, MD, MSc
principal investigator · Lady Davis Institute, McGill University, Jewish General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion